ITP Registry and Accompanying Biospecimen Collection
ITP-Registry
Multicenter National ITP Registry and Accompanying Biospecimen Collection
1 other identifier
observational
1,100
1 country
64
Brief Summary
The objective of this ITP registry is to collect clinical information, including biosampling, from consenting patients with a variety of ITPs at different points in the course of their disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2021
Longer than P75 for all trials
64 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 23, 2021
CompletedStudy Start
First participant enrolled
November 29, 2021
CompletedFirst Posted
Study publicly available on registry
December 9, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
April 1, 2027
July 15, 2025
July 1, 2025
4.8 years
November 23, 2021
July 10, 2025
Conditions
Outcome Measures
Primary Outcomes (6)
epidemiological data on ITP - Incidence
Incidence: number of reported ITP, estimate incidence by zip code area
At enrollment
epidemiological data on ITP - Age
Age (year of birth)
At enrollment
epidemiological data on ITP - Sex distribution
Sex distribution: female, male
At enrollment
Description of the causes of ITP
causes of ITP in primary/secondary form (medical induced, autoimmune disease, Lymphoma / malignancy, infection, upon vaccination, others)
At enrollment
ITP treatment type received
Medical therapies received
5 years
Remission
Remission Status
5 years
Secondary Outcomes (12)
Recording of clinical characteristics of affected patients - Disease stage
At enrollment, 6 months, annually up to 5 years
Recording of clinical characteristics of affected patients- platelet counts
At enrollment, 6 months, annually up to 5 years
Recording of clinical characteristics of affected patients -disease manifestation at diagnosis
At enrollment
Bleeding events
At enrollment, 6 months, annually up to 5 years
thromboembolic events
At enrollment, 6 months, annually up to 5 years
- +7 more secondary outcomes
Eligibility Criteria
Patients with Immune thrombocytopenia (ITP) which is a rare hematologic disorder that can lead to a greater risk of bleeding or a prolonged bleeding time due to an autoimmune-mediated deficiency of platelets. There is a distinction between a primary form, in which no triggering cause is identifiable, and secondary forms, which may for example occur in the context of systemic autoimmune diseases or drug-induced.
You may qualify if:
- Primary or secondary Immune Thrombocytopenia (ITP)
- Age ≥18 years
- signed declaration of consent
You may not qualify if:
- diagnoses that cannot be reconciled with the diagnosis of ITP (esp. heparin-induced thrombocytopenia, pregnancy-associated thrombocytopenia, pseudothrombocytopenia)
- no informed consent possible (this covers patients who are unable to understand the nature and scope of participation)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Jena University Hospitallead
- University Hospital Dresdencollaborator
- Novartiscollaborator
- Swedish Orphan Biovitrumcollaborator
- Grifols Biologicals, LLCcollaborator
- Amgencollaborator
- argenxcollaborator
Study Sites (64)
Universitätsklinikum Aachen AöR
Aachen, 52074, Germany
Klinikum Altenburger Land GmbH, Klinik für Innere Medizin/Hämatologie/Onkologie
Altenburg, 04600, Germany
MVZ am Klinikum Aschaffenburg
Aschaffenburg, 63739, Germany
MVZ IMD GmbH, IMD Gerinnungszentrum Hochtaunus
Bad Homburg, 61352, Germany
Onkologie/Hämatologie
Bad Liebenwerda, 04924, Germany
Charité Universitätsmedizin Berlin
Berlin, 10117, Germany
Praxis für Hämatologie und Onkologie Berlin-Mitte
Berlin, 10117, Germany
Vivantes Netzwerk für Gesundheit GmbH, Klinikum am Friedrichshain
Berlin, 10249, Germany
Onkologie am Segelfliegerdamm
Berlin, 12487, Germany
MVZ Hämatologikum GmbH
Biberach, 88400, Germany
Augusta-Kranken-Anstalt gGmbH
Bochum, 44791, Germany
Klinikum Chemnitz gGmbH
Chemnitz, 09116, Germany
MVZ Klinikum Coburg GmbH
Coburg, 96450, Germany
Klinikum Darmstadt
Darmstadt, 64283, Germany
ARGE e.V.
Donauwörth, 86609, Germany
Onkozentrum Dresden/Freiberg
Dresden, 01127, Germany
Gemeinschaftspraxis Hämatologie-Onkologie
Dresden, 01307, Germany
Gemeinschaftspraxis Mohm & Prange-Krex
Dresden, 01307, Germany
Universitätsklinikum Dresden
Dresden, 01307, Germany
Krankenhaus Düren gGmbH
Düren, 52351, Germany
Onkologische Praxis Erfurt
Erfurt, 99084, Germany
Universitätsklinikum Erlangen
Erlangen, 91054, Germany
MVZ für Hämatologie und Onkologie Essen
Essen, 45136, Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, 60590, Germany
Haemostas-Frankfurt
Frankfurt am Main, 60596, Germany
PIOH Studien und Management GbR
Frechen, 50226, Germany
Fachärztliche Gemeinschaftspraxis Panagiotou/Minaei
Garbsen, 30823, Germany
IOGP Gera MVZ GmbH
Gera, 07548, Germany
ALB FILS Kliniken, Klinik am Eichert
Göppingen, 73035, Germany
Universitätsklinik Greifswald
Greifswald, 17475, Germany
Katholisches Krankenhaus Hagen gGmbH
Hagen, 58097, Germany
Gemeinschaftspraxis, FA für Innere Medizin
Halle, 06110, Germany
MVZ III Onkologie der evidia MVZ Halle (Saale) GmbH
Halle, 06110, Germany
Onko-Kolleg GmbH & Co. KG, HOPA MVZ GmbH
Hamburg, 22767, Germany
Werlhof-Institut MVZ GmbH
Hanover, 30159, Germany
Onkologie am Raschplatz
Hanover, 30161, Germany
Dres. Kamal & Dorn GbR
Hanover, 30625, Germany
ODZ-Petersen GmbH
Heidenheim, 89522, Germany
St. Bernward Krankenhaus GmbH
Hildesheim, 31134, Germany
Klinikum Idar-Oberstein GmbH
Idar-Oberstein, 55743, Germany
University Hospital Jena
Jena, 07745, Germany
Klinikum Kassel GmbH
Kassel, 34125, Germany
Universitätsklinikum Schleswig-Holstein
Kiel, 24105, Germany
Gemeinschaftsklinikum Mittelrhein gGmbH, Ev. Stift St. Martin
Koblenz, 56073, Germany
Ambulantes Zentrum für Hämatologie, Onkologie und Gerinnung
Kronach, 96317, Germany
MVZ mbH, Onkologische Schwerpunktpraxis
Leer, 26789, Germany
Universitätsklinikum Leipzig
Leipzig, 04103, Germany
OnkoFor Leipzig GmbH
Leipzig, 04289, Germany
Universitätsklinikum Magdeburg, Klinik für Hämatologie, Onkologie und Zelltherapie
Magdeburg, 39120, Germany
Carl-von-Basedow Klinikum Merseburg
Merseburg, 06217, Germany
Gemeinschaftspraxis Hämato-Onkologie
München, 81241, Germany
Dietrich-Bonhoeffer-Klinikum Neubrandenburg
Neubrandenburg, 17036, Germany
MVZ Onko Medical GmbH Neustadt
Neustadt am Rübenberge, 31535, Germany
Pi.Tri.-Studien GmbH
Offenburg, 77654, Germany
Elblandkliniken Stiftung & Co. KG, Elblandklinikum Riesa
Riesa, 01589, Germany
Klinikum Südstadt Rostock
Rostock, 18059, Germany
Medcenter Nordsachsen
Schkeuditz, 04435, Germany
MVZ am Schlossgarten, Zero Praxen
Schwetzingen, 68723, Germany
Onkologiezentrum Soest/Iserlohn
Soest, 59494, Germany
Bundeswehrkrankenhaus Ulm
Ulm, 89081, Germany
Schwarzwald-Baar. Klinikum Villingen-Schwenningen GmbH
Villingen-Schwenningen, 78052, Germany
Onkologisches Zentrum Wolfsburg-Helmstadt MVZ GmbH
Wolfsburg, 38440, Germany
Universitätsklinikum Würzburg
Würzburg, 97080, Germany
Praxis für Hämatologie und Internistische Onkologie
Zittau, 02763, Germany
Biospecimen
18 mL whole blood (peripheral venipuncture) and 9 ml bone marrow
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Thomas Stauch, Dr. med.
Jena University Hospital
- STUDY DIRECTOR
Karolin Trautmann-Grill, Dr. med.
Dresden Univeristy Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 23, 2021
First Posted
December 9, 2021
Study Start
November 29, 2021
Primary Completion (Estimated)
September 1, 2026
Study Completion (Estimated)
April 1, 2027
Last Updated
July 15, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will not share
There is no validated data sharing procedure at the university hospital Jena. But of course it is planned to share the results with scientific community and publish the data in a scientific journal.